The first of Microbiotica Ltd.’s unique bacterial mixes will reach the clinic within the next two years, for a so-far undeclared indication, says company co-founder and CEO Mike Romanos. “We have a bacterial mix that is curative in animal models, so we should move into preclinical development within the coming year,” he adds.
Microbiotica: Wellcome Spin-Out Exploits Unique Microbe Collection
Emerging Company Profile: Microbiotica, a UK biotech spin-out from the Wellcome Trust Sanger Institute announced late last year, says it has unique capabilities in culturing and sequencing the human bacterial microbiome that will be of use to develop bacterial mixes for therapeutic use.
